240 related articles for article (PubMed ID: 24404140)
1. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.
Orr MT; Beebe EA; Hudson TE; Moon JJ; Fox CB; Reed SG; Coler RN
PLoS One; 2014; 9(1):e83884. PubMed ID: 24404140
[TBL] [Abstract][Full Text] [Related]
2. MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.
Orr MT; Duthie MS; Windish HP; Lucas EA; Guderian JA; Hudson TE; Shaverdian N; O'Donnell J; Desbien AL; Reed SG; Coler RN
Eur J Immunol; 2013 Sep; 43(9):2398-408. PubMed ID: 23716300
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.
Orr MT; Fox CB; Baldwin SL; Sivananthan SJ; Lucas E; Lin S; Phan T; Moon JJ; Vedvick TS; Reed SG; Coler RN
J Control Release; 2013 Nov; 172(1):190-200. PubMed ID: 23933525
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.
Baldwin SL; Reese VA; Larsen SE; Beebe E; Guderian J; Orr MT; Fox CB; Reed SG; Coler RN
PLoS One; 2021; 16(3):e0247990. PubMed ID: 33705411
[TBL] [Abstract][Full Text] [Related]
5. The importance of adjuvant formulation in the development of a tuberculosis vaccine.
Baldwin SL; Bertholet S; Reese VA; Ching LK; Reed SG; Coler RN
J Immunol; 2012 Mar; 188(5):2189-97. PubMed ID: 22291184
[TBL] [Abstract][Full Text] [Related]
6. Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.
Orr MT; Beebe EA; Hudson TE; Argilla D; Huang PW; Reese VA; Fox CB; Reed SG; Coler RN
Vaccine; 2015 Nov; 33(48):6570-8. PubMed ID: 26541135
[TBL] [Abstract][Full Text] [Related]
7. Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.
Duthie MS; Coler RN; Laurance JD; Sampaio LH; Oliveira RM; Sousa AL; Stefani MM; Maeda Y; Matsuoka M; Makino M; Reed SG
Infect Immun; 2014 Sep; 82(9):3979-85. PubMed ID: 25024362
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K.
Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Cho SN; Coler RN; Reed SG; Shin SJ
Vaccine; 2016 Apr; 34(19):2179-87. PubMed ID: 27005808
[TBL] [Abstract][Full Text] [Related]
9. Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model.
Kwon KW; Lee A; Larsen SE; Baldwin SL; Coler RN; Reed SG; Cho SN; Ha SJ; Shin SJ
Sci Rep; 2019 Oct; 9(1):15560. PubMed ID: 31664157
[TBL] [Abstract][Full Text] [Related]
10. Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells.
Baldwin SL; Ching LK; Pine SO; Moutaftsi M; Lucas E; Vallur A; Orr MT; Bertholet S; Reed SG; Coler RN
J Immunol; 2013 Sep; 191(5):2514-2525. PubMed ID: 23904160
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Day TA; Penn-Nicholson A; Luabeya AKK; Fiore-Gartland A; Du Plessis N; Loxton AG; Vergara J; Rolf TA; Reid TD; Toefy A; Shenje J; Geldenhuys H; Tameris M; Mabwe S; Bilek N; Bekker LG; Diacon A; Walzl G; Ashman J; Frevol A; Sagawa ZK; Lindestam Arlehamn C; Sette A; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2021 Apr; 9(4):373-386. PubMed ID: 33306991
[TBL] [Abstract][Full Text] [Related]
13. Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.
Baldwin SL; Reese VA; Huang PW; Beebe EA; Podell BK; Reed SG; Coler RN
Clin Vaccine Immunol; 2016 Feb; 23(2):137-47. PubMed ID: 26656121
[TBL] [Abstract][Full Text] [Related]
14. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.
Coler RN; Day TA; Ellis R; Piazza FM; Beckmann AM; Vergara J; Rolf T; Lu L; Alter G; Hokey D; Jayashankar L; Walker R; Snowden MA; Evans T; Ginsberg A; Reed SG;
NPJ Vaccines; 2018; 3():34. PubMed ID: 30210819
[TBL] [Abstract][Full Text] [Related]
15. Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy.
Gupta N; Vedi S; Kunimoto DY; Agrawal B; Kumar R
Vaccine; 2016 Nov; 34(46):5677-5688. PubMed ID: 27693020
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
[TBL] [Abstract][Full Text] [Related]
17. Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses.
Seydoux E; Liang H; Dubois Cauwelaert N; Archer M; Rintala ND; Kramer R; Carter D; Fox CB; Orr MT
J Immunol; 2018 Jul; 201(1):98-112. PubMed ID: 29769270
[TBL] [Abstract][Full Text] [Related]
18. Toll like-receptor agonist Pam
Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
[TBL] [Abstract][Full Text] [Related]
19. Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.
Windish HP; Duthie MS; Misquith A; Ireton G; Lucas E; Laurance JD; Bailor RH; Coler RN; Reed SG
Vaccine; 2011 Oct; 29(44):7842-8. PubMed ID: 21816196
[TBL] [Abstract][Full Text] [Related]
20. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ
PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
